Attorney Docket No. P51330

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Thompson et al.

September 11, 2007

Serial No.:

10/508,893

Group Art Unit No.: 1625

Filed:

January 26, 2005

Examiner: T. V. Oh

For:

ACID AND ESTER COMPOUNDS AND METHODS OF USING THE

SAME

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT AND REQUEST FOR REJOINDER

Sir,

This paper is in response to the Restriction Requirement mailed August 23, 2007, having a shortened statutory period for reply of 1 month. Claims 1-23, 25-47, and 56-58 are pending in the application. Claims 1-23, 25-47, and 56-58 are subject to a restriction requirement and/or election requirement.

Restriction to one of the following is required under 35 U.S.C. §121 and 372:

Group I. Claims 1-23, drawn to the non-hetero containing various aliphatic and cyclic compounds following compound formula (I) as disclosed below:

$$(R^3)_k$$
 $(R^3)_k$
 $(CR^4R^5)_n$
 $(CR^8R^9)_q$
 $(CR^8R^9)_q$

Serial No.: 10/508,893 Group Art Unit No.: 1625

Group II. Claims 1-21 and 23, drawn to the hetero cyclic compound following compound formula (I) as disclosed below:

$$(R^3)_k$$
 $(R^3)_k$
 $(CR^4R^5)_n$
 $(CR^8R^9)_q$
 $(CR^8R^9)_q$

Group III. Claims 25-47 is drawn to the method of the prevention or treatment of an LXR mediated disease by using non-hetero compound containing various aliphatic and cyclic compound following compound formula (I) as disclosed below:

$$R^{10} O (CR^{1}R^{2})_{p} Z O (CR^{4}R^{5})_{n} N R^{7} CCR^{8}R^{9})_{q}$$

Group IV. Claims 25-41, and 43-47, drawn to the method of the prevention or treatment of an LXR mediated disease by using hetero compounds containing various heterocyclic compounds following compound formula (I) as disclosed below:

$$(R^3)_k$$
 $(R^3)_k$
 $(CR^4R^5)_n$
 $(CR^8R^9)_q$
 $(CR^8R^9)_q$